Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to
erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The
primary endpoint is Overall Survival (OS).